Keros Therapeutics (NASDAQ:KROS) Shares Gap Up – Should You Buy?

Keros Therapeutics, Inc. (NASDAQ:KROS)’s share price gapped up prior to trading on Thursday . The stock had previously closed at $10.33, but opened at $11.67. Keros Therapeutics shares last traded at $12.40, with a volume of 3,289,143 shares trading hands.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on KROS shares. Truist Financial cut their price target on Keros Therapeutics from $43.00 to $25.00 and set a “buy” rating on the stock in a report on Wednesday. Piper Sandler cut their target price on Keros Therapeutics from $40.00 to $15.00 and set an “overweight” rating on the stock in a report on Friday, January 17th. HC Wainwright restated a “buy” rating and set a $40.00 price target on shares of Keros Therapeutics in a research note on Tuesday, April 1st. Wells Fargo & Company dropped their price objective on shares of Keros Therapeutics from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday, February 27th. Finally, Wedbush reiterated a “neutral” rating and set a $15.00 price objective on shares of Keros Therapeutics in a report on Tuesday, April 1st. Six equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $40.33.

Keros Therapeutics Stock Performance

The company’s 50 day simple moving average is $10.91 and its 200 day simple moving average is $30.80. The stock has a market cap of $494.05 million, a PE ratio of -2.34 and a beta of 1.39.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($1.14) EPS for the quarter, beating analysts’ consensus estimates of ($1.36) by $0.22. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The company had revenue of $3.04 million during the quarter, compared to the consensus estimate of $37.32 million. Equities research analysts expect that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current year.

Institutional Trading of Keros Therapeutics

A number of large investors have recently added to or reduced their stakes in KROS. Braidwell LP grew its position in shares of Keros Therapeutics by 167.9% during the 4th quarter. Braidwell LP now owns 1,894,439 shares of the company’s stock valued at $29,989,000 after acquiring an additional 1,187,199 shares during the period. Lynx1 Capital Management LP purchased a new position in Keros Therapeutics in the fourth quarter valued at approximately $8,612,000. Millennium Management LLC grew its holdings in Keros Therapeutics by 53.3% during the fourth quarter. Millennium Management LLC now owns 878,159 shares of the company’s stock valued at $13,901,000 after purchasing an additional 305,169 shares during the period. Boxer Capital Management LLC purchased a new stake in Keros Therapeutics in the fourth quarter worth $3,958,000. Finally, Integral Health Asset Management LLC raised its stake in shares of Keros Therapeutics by 125.0% in the fourth quarter. Integral Health Asset Management LLC now owns 450,000 shares of the company’s stock valued at $7,124,000 after buying an additional 250,000 shares during the period. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.